Fewer Wuhan Patients For Gilead Remdesivir Study: WHO

China Coronavirus Studies Surge

In a shocking and revealing account, a primary investigator of the front-runner antiviral drug for the coronavirus in China expresses concerns over finding enough patients for the study Wuhan, the outbreak's epicenter.

CHINA CORONAVIRUS-RELATED STUDIES JUMP FIVE-FOLD TO NEARLY 200 IN TWO WEEKS • Source: Chinese clinical trials registry website

While China has confirmed that coronavirus cases are dropping outside Wuhan and Hubei province, the numbers are now spiking outside China. One of the leading antiviral hopes for the spreading outbreak, Gilead Sciences Inc.’s remdesivir, is now in a Phase III study in Wuhan after being used to treat the first confirmed patient in the US with promising results.

Surprisingly, the Wuhan study with the drug has encountered challenges including finding enough patients to enroll, noted a World Health...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from China

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By 

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia